The effect of azacitidine treatment on upregulating SHP-1 was confirmed in CD8+ T cells collected from a LGLL patient harboring STAT3Y640F mutation, suggesting that azacitidine may be used to target STAT3 mutated cells in LGLL patients. The gene discussed is CD8A; the disease is T-cell large granular lymphocyte leukemia.